

Focusing the clinical response
Can Differentiated care accelerate the implementation of HIV treatment for all?

Eric Goemaere, IAPAC Symposium, Geneva Oct 13th 2016
Southern African MSF medical unit, School of public health, Cape Town university


Facility-based individual

Out-of-facility individual

Framework for differentiated approach to care

- Different Care package elements for different PLHIV categories
- 1. Patients presenting well
- 2. Patients presenting with advanced HIV infection
- 3. Stable patients on ART stable
- 4. Patients on ART with complex problems


Fig. 3. Key factors in differentiated approaches to HIV care





HIV care for epidemic control

Ambitions vs reality






Treatment cascade or treatment cliff? Successful HIV treatment, as measured by an undetectable viral load, is key for epidemic control.

Reaching the 90:90:90 UNAIDS targets will require considerable future commitment and investment.

ART treatment cascade: focus on back end





Main MSF models of differentiated ART delivery

Aim: reduce burden for patients AND health care workers

Adherence Clubs



Delinking clinical consultation from ART refill for stable patients on ART



Community ART

Distribution

Health Service Driven

Appointment

spacing and


Patient Driven

Community ART

Groups (CAGs)

	fast-track drug refill	Facility-based clubs	Community- based clubs	Points (PODI)	
Context	Urban & rural	Urban & rural		Urban	Rural
ART refill	1 to 3-monthly	2-6 monthly		3-monthly	1 to 3 Monthly
Mode	Individual	Group		Individual	Group
Where	Health facility	Health facility or community venues		Community distribution points	Patients' homes
Led by	CHW	CHW		Expert patients	Expert patients
Clinical consultation	Yearly	Yearly		Yearly	Yearly
Blood drawing	Yearly viral load	Yearly viral load		Yearly viral load	Yearly viral load
JANS PROMIERES			<u> </u>	<u> </u>	

Designing the appropriate model: logical framework



The building blocks



"The amount of time we spend at the health facility in the queues —it's too much time. I want to come to the facility only twice a year... I have a life to live."

- Patricia Asero Achieng, PLHIV, Kenya



AN ONLINE KNOWLEDGE REPOSITORY FOR DIFFERENTIATED CARE

This is the go-to resource and online recipe book for implementing differentiated models of antiretroviral therapy (ART) delivery.

Visit www.differentiatedcare.org



DIFFERENTIATED CARE FOR HIV:


A DECISION FRAMEWORK FOR ANTIRETROVIRAL THERAPY DELIVERY

It's time to deliver differently

Can we have 70 -80 % of all ART chronic patients on community models?

City of Cape Town, South Africa








data sources: sinjani.pgwc.gov.za; community club registers

Better retention than conventional care



Clinical outcomes may in fact be superior when it comes to selected outcomes such as retention in HIV care and viral suppression (Khayelitsha and Kinshasa)
In building decentralized ART delivery, adherence, and retention in care support, community-based ART programs encourage patient autonomy, build social networks, and minimize the structural barriers, such as cost of transport to the clinic, which in turn appear to result in better outcomes

Nachega, J.B., Adetokunboh, O., Uthman, O.A. et al. Curr HIV/AIDS Rep 2016

Policy and ressources: critical enablers



Task shifting to community health workers



Acces to quality clinical management



Cost per	patient /	/year
----------	-----------	-------

374 US\$

Adherence club 300 US\$


Conventional care



Robust drug supply


Cost-effectiveness and access analysis from Khayelitsha Adherence clubs Funeka Bango and all , UCT Health Economics Unit

ART treatment cascade: focus on front doors





Not everyone is equal when looking at HIV transmission Community survey, KZN, South Africa, 2013



Moving differentiated care at front end of cascade, PLHA's with VL > 1000 cp/ml, Eshowe, KZN, SA 2016


CASCADE OF CARE, MSF ESHOWE PROJECT, Q2 2016


HIV CARE FOR EPIDEMIC CONTROL: AMBITIONS VS REALITY




Diagnosed/Not A

Undiagnosed









WITH AN UNDETECTABLE VIRAL LOAD (10 691 PLWHIV)

HIV Treatment Cascade in Eshowe, KZN





Number of yearly ART initiations

Eshowe, KZN, South Africa



Enhanced linkage to care <> community initiation Tete, Mozambique <> Khayelitsha , South Africa







Mobile community testing / POC CD4

Staffed by lay HCWs + nurse

CD4>350

CD4<350 (or choice)




Refer to closest clinic with linkage support strategy ->SOC

CHW	Mobile 1	Mobile 2	Fixed site	
lients tested HIV+ in Q1 2013 who were referred to		40	06	
52	05	49	96	
20	29	14	46	
32	36	35	50	
38%	45%	29%	48%	
	52 20 32	52 65 20 29 32 36	52 65 49 20 29 14 32 36 35	

Slide courtesy of Lynne Wilkinson

Ongoing advanced HIV disease presentations despite increasing median CD4 at initiation . Western Cape , South Africa






Community CD4 count as a marker of morbidity potential: Results from the Western Cape, South Africa. M. Osler, A.Boulle, UCT


Stage IV disappeared in some countries with ARV coverage ...but not in others

Number of cases of AIDS-related extrapulmonary cryptococcosis cases. Sao Paulo, 1982–2010. Jose E. Vidal Braz J Infect Dis. 2013; 17(3): 353–362







ART treatment cascade







Front door: Evolution of late presenters ratio (CD4< 100) Health centers levels in 2 capital cities









Conakry- 5 facilities – 6553 ever


initiated – low prevalence

Kinshasa – 6 facilities 9179 ever initiated – low prevalence


Source: Tier.net monitoring, Cider, UCT, Katherine Hilderbrand



HIV-Related Medical Admissions in 3 referral hospitals Cape Town, SA, Kinshasa, DRC and Homa Bay, Kenya




Mortality: 20 % but at 90 days follow
 -up, 29.9% required readmission and
 13.3% died.





 Post discharge mortality: unknown .Probably reaches up to 40 %




Late presenters proposed screening package PHC level (< 100 Cd4 or symptomatic)

Semi –quant CD4 LFA



Minimal PHC screening package

- >semi quantitative CD4 LFA
- >TB LAM test : GeneXpert acces
- CRAG test
- >TDF blood level tests (DBS)
- **→**Point mutation genotype?
- + Clinical management of non naïve patients including referral criteria + aggressive approach (counselling, VL algorithm, 2nd line switch)



CRAG



TB -LAM (< 100 Cd4)





CLINICAL MANAGEMENT OF PATIENTS WITH ADVANCED HIV DISEASE

(i.e. those presenting with CD4 count < 200 CD4 cells/mm3 or WHO Stage III & IV defining illness)

IMPORTANT BASICS

- Perform a thorough clinical examination.
- Check all 4 vital signs: pulse, respiratory rate, temperature and blood pressure.
- Rehydrate if signs of dehydration (due to diarrhea, vomiting, or other causes).
- Admit a clinically unstable patient to hospital!
- Sepsis is common in advanced disease. If a fever is present, examine thoroughly to find the site. If there is likely to be a delay in admission and a severe bacterial infection is suspected (e.g. pneumonia), give the first dose of antibiotics i.m. or i.v. e.g. ceftriaxone
- Respiratory disease is also common in advanced disease. Consider especially TB and bacterial or pneumocystis pneumonia (PCP). Administer oxygen if short of breath (including nasal flaring in children) and owner saturation <90% (strongly consider PCP). If respiratory rate > 30 admit to hospital

EVALUATE FOR EPTB

FIRST X-RM presentations of PTB in HIV patients are well characterized









In patients with

CD4 < 100, test

disseminated

TB antigen with

Determine TB LAM

urine for

SCREEN AND EVALUATE FOR PULMONARY TB

CHEST X-RAYS features of EPTB



Large heart in TB perical TB-related pleural Needle aspiration dfis (especially if symmetrical and rounded)



ABDOMINAL TB CAREFUL

for abdominal tendemess (especially epigastric area) can Indicate organomegaly and/or abdominal lymp nodes due to EPTP Confirm If Passible with sound

REEN all patients with CD4 < 100 with a rapid serum or plasma CrAg test. If positive, need to decide if patient might is cryptococcal meningitis:

1. LUMBAR PUNCTURE (LP) should be performed in all those wit headache, confusion, and/or change in behaviour, provided that capacity exists and there are no contraindications 1:

Test CSF for evidence of:

- CCM, preferably with a rapid CrAg assay
- bacterial meningitis
- TB moningitis (TBM)
- 2. If CrAg+ and none of above symptoms, give 'pre-emptive' antifungal therapy2 (see WHO rapid advice algorithm, 2011)

BE AWARE OF THE SYMPTOMS OF TOXOPLASMOSIS

Any person with focal neurological impairment - "stroke", weak limb(s), co-ordination problems, facial weakness, speech difficulty - may have an intracranial lesion due to one of several infections, including toxoplasmosis, and should be referred urgently for more comprehensive evaluation

EVALUATE VISION AND REFER, ESPECIALLY IF RECENT DETERIORATION

CMV retinitis can cause permanent blindness if left untreated. examine the fundi yourself using an ophthalmoscope and dilying os (cyclopentolate or tropicamide) or refer for fuller evaluation and









CHECK PALATE AND SKIN for purplish lesions of Kaposi's Sarcoma





LATE PRESENTERS' NEED

All patients with advanced hiv disease need antiretroviral therapy (ART)

- Initiate within 2 weeks if possible.
- Important exceptions:

Wait 4-6 weeks after initiation of treatment for TB and cryptococcal meningitis to avoid life-threatening intracranial IRIS Wait 2 weeks after initiation of all other TB treatment if CD4 < 50 Wait 2-8 weeks after initiation of all other TB if CD4 > 50







Conclusions

- Differentiated models of care can help to accelerate the 90 90-90 by
 - offloading workload from overburden health services
 - increasing social fabric and adherence
- differentiated models also apply at front end of cascade (non sick, non health seeking clients) and central part (care)
- Aids is not over in SS Africa: still unacceptable number of deaths! Advanced HIV diseases management remains an ongoing priority
- we need new tools like new diagnostics and ARV formulation compound including long acting injectable/ implants as well as new delivery models to control this pandemic.



Aknowledgments

- Graeme Meintjes, Katherine Hilderbrand,
 Andrew Boulle, Meg Osler, UCT, Cape town
- MSF teams in Khayelitsha ,Eshowe and Kinshasa
- David Maman, Aline Niyibizi, Epicentre
- Jean Nachega, Stellenbosch University
- SAMU team mates